SETD7 Rabbit Monoclonal Antibody for WB and ELISA - Q8WTS6

Core Product Specifications and Parameters

Biological Background: SETD7 Function and Localization

• SETD7 (also known as KMT7, SET7/9) is a histone-lysine N-methyltransferase containing a catalytic SET domain, belonging to the SET domain methyltransferase family.
• It specifically monomethylates histone H3 at lysine 4 (H3K4me1), a modification commonly associated with transcriptionally active chromatin. Related references: PMID:11779497 PMID:11850410 PMID:12540855 PMID:12588998 PMID:16141209
• Plays a central role in the transcriptional activation of specific genes, including collagenase and insulin; recruited by IPF1/PDX-1 to the insulin promoter to stimulate transcription. Related references: PMID:12588998 PMID:16141209
• SETD7 additionally methylates multiple non-histone substrates such as p53/TP53 (at Lys-372), TAF10 (Lys-189), CGAS (Lys-491), and GLI3, often recognizing a [KR]-[STA]-K consensus motif; these modifications influence protein stability, transcriptional activity, and DNA binding. Related references: PMID:15099517 PMID:15525938 PMID:16415881 PMID:17108971 PMID:27146893
• Localizes predominantly to the nucleus and is associated with chromosomes.
• Widely expressed across tissues, with notable expression in pancreatic islets.

Experimental Guidance and Technical Tips

• The immunogen corresponds to an N-terminal peptide (aa 1–100) of human SETD7, which may contribute to targeting the native protein; confirm specificity in your experimental system.
• For Western blotting, consider using whole-cell lysates or nuclear-enriched fractions from human, mouse, or rat cell lines, as cross-reactivity has been observed.
• Validate the optimal antibody dilution and detection conditions empirically, especially when using ELISA or analyzing low-abundance samples.
• Given SETD7’s nuclear localization, subcellular fractionation may improve signal detection.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio streamlines IVD raw material procurement with a comprehensive portfolio that includes validated antibody pairs, optimized monoclonal and polyclonal antibodies, and bulk ancillary reagents. This SETD7 antibody supports epigenetic and transcription research, and is backed by CamelBio’s supply chain expertise, enabling reliable access to both common and rare target reagents. From early-stage discovery to clinical applications, CamelBio serves as a trusted sourcing partner to accelerate your diagnostic development.